PBYIPUMA BIOTECHNOLOGY, INC.

Nasdaq pumabiotechnology.com


$ 3.84 $ 0.04 (1.05 %)    

Friday, 31-May-2024 15:59:53 EDT
QQQ $ 454.82 $ -0.84 (-0.19 %)
DIA $ 398.57 $ 6.05 (1.59 %)
SPY $ 530.36 $ 4.76 (0.91 %)
TLT $ 91.26 $ 0.61 (0.68 %)
GLD $ 225.37 $ -1.27 (-0.59 %)
$ 3.85
$ 3.88
$ 0.00 x 0
$ 0.00 x 0
$ 3.77 - $ 3.94
$ 2.13 - $ 7.73
208,920
na
185.53M
$ 1.02
$ 12.07
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-02-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-02-2023 09-30-2023 10-Q
4 08-03-2023 06-30-2023 10-Q
5 05-04-2023 03-31-2023 10-Q
6 03-02-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-04-2022 06-30-2022 10-Q
9 05-05-2022 03-31-2022 10-Q
10 03-03-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-06-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-05-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-28-2020 12-31-2019 10-K
19 11-07-2019 09-30-2019 10-Q
20 08-09-2019 06-30-2019 10-Q
21 05-10-2019 03-31-2019 10-Q
22 03-01-2019 12-31-2018 10-K
23 11-05-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-10-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-09-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-01-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 02-29-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-02-2015 12-31-2014 10-K
39 11-10-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 puma-biotechnology-to-join-russell-3000-index

Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the...

 pfizer-wins-1075m-verdict-against-astrazeneca-over-cancer-drug-patent-dispute

A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infri...

 hc-wainwright--co-reiterates-buy-on-puma-biotechnology-maintains-7-price-target

HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price t...

Core News & Articles

- Reuters

 hc-wainwright--co-reiterates-buy-on-puma-biotechnology-maintains-7-price-target

HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $7 price t...

 puma-biotechnology-sees-q2-net-product-revenue-43m-45m-fy24-net-product-revenue-183m-190m

Second Quarter and Full Year 2024 Financial Outlook Second Quarter 2024Full Year 2024Net Product Revenue$43 -45 million$183 - $...

 puma-biotechnology-q1-2024-adj-eps-005-beats-022-estimate-sales-43800m-beat-41050m-estimate

Puma Biotechnology (NASDAQ:PBYI) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(...

 hc-wainwright--co-maintains-buy-on-puma-biotechnology-lowers-price-target-to-7

HC Wainwright & Co. analyst Edward White maintains Puma Biotechnology (NASDAQ:PBYI) with a Buy and lowers the price targ...

 puma-biotechnology-q4-2023-adj-eps-0310-beats-0300-estimate-sales-72200m-miss-73550m-estimate

Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.310 per share which beat the analyst consensus estimate of $...

 earnings-scheduled-for-february-29-2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on reve...

 hc-wainwright--co-reiterates-buy-on-puma-biotechnology-maintains-8-price-target

HC Wainwright & Co. analyst Edward White reiterates Puma Biotechnology (NASDAQ:PBYI) with a Buy and maintains $8 price t...

 puma-biotechnology-announces-phase-ii-clinical-trial-design-for-alisertib-in-her2-negative-hormone-receptor-positive-metastatic-breast-cancer-plans-to-initiate-trial-in-h2-2024

Patients will be dosed with alisertib given at either 30 mg, 40 mg or 50 mg twice daily (BID) on days 1-3, 8-10 and 15-17 on a ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION